GargSK, WeinzimerSA, TamborlaneWV, BuckinghamBA, BodeBW, BaileyTS, BrazgRL, IlanyJ, SloverRH, AndersonSM, BergenstalRM, GrosmanB, RoyA, CorderoTL, ShinJ, LeeSW, and KaufmanFR: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
2.
GargSK, Wernicke-PantenK, RojeskiM, PierreS, KirchheinY, JedynastyK: Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 1 diabetes also using insulin glargine—SORELLA 1 study. Diabetes Technol Ther, 2017; 19:516–526.
3.
GargSK, HenryRR, BanksP, BuseJB, DaviesMJ, FulcherGR, PozzilliP, Gesty-PalmerD, LapuertaP, SimóR, DanneT, McGuireDK, KushnerJA, PetersA, StrumphP.Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med, 2017 Sep 13, doi:10.1056/NEJMoa1708337.
4.
GargSK: Expanding treatment options for improving health outcomes in type 1 diabetes. Diabetes Technol Ther, 2017; 19:549–551.
